Ocuphire Pharma Investor Updates slide image

Ocuphire Pharma Investor Updates

P 29 Presbyopia Eye Drops Competitive Landscape Validation of Pupil Modulating Drops Achieving Pin-Hole Effect & Efficacy, Many with Pilocarpine Pupil modulation MOA Soften lens MOA Combination drugs *act on sphincter and ciliary muscles in dose- dependent manner Cholinergic Agonist* (pilocarpine) Other Cholinergic Agonists* Visus (BrimocholⓇ; brimonidine + carbachol) Orasis (CSF-1; Low dose pilo) Allergan (AGN-190584; 1.25% pilo) Eyenovia (MicroLine; 1 or 2% pilo) NDA Phase 3 Phase 2 Phase 1 Lenz (PRX-100; aceclidine) Novartis (EV-06) Ocuphire (0.75% Nyxol + 0.4% pilo) Ocuphire is differentiated by using both the dilator and sphincter muscles moderately to reach a pin-hole pupil size Alpha Antagonist & pilocarpine* Corporate Websites, Grzybowski, A, Markeviciute A, Zemaitiene R. A Review of Pharmacological Presbyopia Treatment. 2020 Ocuphire PHARMA
View entire presentation